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ABSTRACT The European Respiratory Society (ERS) International Congress is the largest respiratory
congress and brings together leading experts in all fields of respiratory medicine and research. ERS
Assembly 3 shapes the basic and translational science aspects of this congress, aiming to combine cutting-
edge novel developments in basic research with novel clinical findings. In this article, we summarise a
selection of the scientific highlights from the perspective of the three groups within Assembly 3. In
particular, we discuss new insights into the pathophysiology of the human alveolus, novel tools in
organoid development and (epi)genome editing, as well as insights from the presented abstracts on novel
therapeutic targets being identified for idiopathic pulmonary fibrosis.
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CONGRESS HIGHLIGHTS
BASIC AND TRANSLATIONAL SCIENCE
Group 3.1. molecular pathology and functional genomics
The pathophysiology of the human lung alveolus
One of the basic science highlights of the European Respiratory Society (ERS) International Congress 2018
in Paris was the hot topic symposium “The pathophysiology of the human lung alveolus”. In this session
four expert speakers presented their recent scientific advances in lung development, repair and
regeneration, published as high-impact papers in 2018, to the general respiratory community.
In the first talk, NIKOLIĆ et al. [1, 2] presented their work on human lung development. Until recently,
most of our knowledge of lung development was based almost exclusively on mouse studies. Molecular
studies using human embryonic and fetal lungs were surprisingly rare. Studying normal human lung
development on a molecular and cellular level is an essential part of regenerative medicine and meaningful
translational studies, with recent evidence suggesting that events in embryonic development contribute to
some adult lung diseases later in life [3]. As lung transplantation is a high-risk procedure for a minority of
patients with a 5-year survival rate of only 54% [4], there is an urgent need to develop new treatment
strategies for patients with end-stage respiratory failure. The most important epithelial stem population in
the developing lung is found within the branching tip, and gives rise to all the various epithelial cell types
in the adult lung, including alveolar and bronchiolar cells [5]. Expression of specific classical markers
identified from mouse lung development were shown to be slightly different in human embryonic tip cells
[2, 6, 7], and a wider comparison between mouse and human lung bud tip stem cells found that 96% of
orthologous genes were shared, but that there were various differences which are likely to have functional
consequences [2]. Self-renewal and differentiation of organoid three-dimensional (3D) culture of these
lung bud tip stem cells from human fetal lung tissue was achieved by using a human-specific combination
of growth factors and signalling inhibitors [2, 6], with a different combination of growth factors required
for mouse tip stem cell renewal [8]. This supports the finding that the transcriptional differences between
mouse and human are functionally relevant. The organoid culture system provides a novel tool for
studying human lung development in vitro. Other culture systems include the use of alginate beads [9, 10],
culture of lung explants [11–16], culture in the mouse kidney capsule [2, 17–19] and co-culture with
matrix-embedded fibroblasts [20]. Such methods allow study of the virtually unexplored period of human
lung development after 20 weeks of development, by using less than 20-week-old lung tissue and maturing
it to a developmental stage at which conditions such as bronchopulmonary dysplasia can be studied.
Next, Melanie Königshoff discussed the role of the WNT pathway in initiating alveolar repair in chronic
obstructive pulmonary disease (COPD). This was studied by using fresh human lung tissue from surgical
samples and then cutting it into precision-cut lung slices [21]. Subsequent 3D culture showed that WNT
activation led to increased expression of both type 1 and type 2 alveolar cell markers; with more severe
emphysematous disease, this occurred to a lesser degree. Lung repair in the adult COPD lung was
associated with a reduction in WNT/β-catenin signalling in the alveolus, and activation of the WNT/
β-catenin pathway was found to initiate alveolar repair in both mouse and patient-derived lung tissue ex
vivo. Tight regulation of WNT/β-catenin signalling was found to be required for alveolosphere formation.
While WNT signalling can activate alveolar repair in vitro, in vivo studies failed to show similar results.
WNT signalling comprises a canonical β-catenin dependent and a noncanonical β-catenin independent
signalling pathway. The Königshoff laboratory showed that noncanonical WNT5A is secreted by
fibroblasts and that its expression is higher in human COPD [22], and also increases with age. This switch
from canonical to noncanonical WNT signalling also occurs in haematopoietic stem cell ageing [23].
Furthermore, WNT5A inhibits canonical WNT signalling in alveolar epithelial cells and compromises
alveolar epithelial cell function [22]. Hence, it was concluded that canonical signalling is required for
development and normal adult lung homeostasis, whereas in lung diseases such as emphysema, canonical
WNT signalling is disrupted. Therapeutic intervention would require the release of WNT5A-driven WNT/
β-catenin inhibition followed by activation of the canonical WNT/β-catenin pathway.
Anjali Jacob discussed the use of induced pluripotent stem cells (iPSCs) to model the human lung alveolar
epithelium [24]. The discovery of iPSCs [25] allowed the possibility of producing isogenic, patient-specific
mature lung epithelial cells that could be used for disease modelling, drug discovery and cell-based
therapy. Cell cultures can be guided from the pluripotent stem cell stage to alveolar epithelium by
recapitulating normal development in a stepwise process termed directed differentiation. Specifically,
surfactant producing type 2 alveolar cells (AEC2s) have been implicated in various lung diseases, such as
interstitial lung diseases (ILDs) and COPD, making iPSC-derived AEC2s a useful tool to study alveolar
diseases. The directed differentiation protocol into functional lamellar body-like containing,
surfactant-secreting and fetal-like SFTPC+ AEC2 takes at least 28 days. WNT activation was required for
efficient production of SFTPC+ distal lung progenitors, but later on a withdrawal of WNT activation
increased the expression of SFTPC+ AEC2 progenitors, illustrating that WNT signalling has different
effects on various stages of the differentiation process.
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Surfactant protein B deficiency, which causes lethal neonatal respiratory distress, was shown as an example
of how iPSC-derived AEC2 cells could be used for disease modelling. Dermal fibroblasts from a patient
with SFTPB-deficiency were reprogrammed into iPSCs and then the 121ins2 mutation was corrected by
gene editing; subsequently, the gene-corrected iPSCs were differentiated into SFTPB-expressing and
lamellar-body containing alveolospheres.
In addition to their use in disease models, human iPSCs can also be used to study human lung
development, and thus complement studies with primary cells from human embryonic and fetal lungs.
Furthermore, this provides an opportunity for improved maturation and validation of iPSC-derived
alveolar cells.
Finally, William Zacharias completed the session by presenting an important study regarding the
regeneration of the lung alveolus after diffuse lung injury, which is a complex and not uniform
regionalised process in which the exquisitely organised alveolar architecture must be regenerated [26] and
probably involves different models of regeneration processes. There are three cell types which are thought
to be involved in alveolar regeneration: 1) in a mouse model of influenza injury, Sox2+ lineage negative
epithelial cells delaminate from the airway, and migrate distally to create Krt5+ pods in the distal lung as a
result of hypoxia, but are unable to recover a normal alveolar structure [26, 27]; 2) the bronchoalveolar
stem cell that is present in the bronchoalveolar duct junction which gets activated after influenza injury
and in vitro can be differentiated to both proximal and distal lineages [28, 29]; and 3) the AEC2 cell is the
major stem cell in the alveolus, as it can both self-renew and differentiate into type 1 cells [30]. A
WNT-responsive subpopulation within the AEC2 population, termed alveolar epithelial progenitor (AEP)
[31, 32], acts as a major facultative progenitor cell in the distal lung which can differentiate and regenerate
injured alveolar epithelium after influenza infection [32]. In addition, AEPs can be isolated by a specific
cell surface marker and grown as 3D organoids in both human and mouse for further functional analysis [32].
Group 3.2. airway cell biology and immunopathology
Organoids, pluripotent stem cells and epigenetic editing
This scientific symposium summarised the latest research on the use of organoids for drug screening and
research, but also on novel tools to modify the genome and epigenome for therapeutic purposes. It was
composed of five expert speakers showing their latest research in this field.
Jeffrey M. Beekman and his co-workers presented the advantages of using intestinal organoids as ex vivo
models for personalised medicine in cystic fibrosis (CF). CF is a monogenetic disease characterised by
mutations in a gene encoding an epithelial chloride channel (the cystic fibrosis transmembrane
conductance regulator (CFTR)) causing thick mucus accumulation and resulting in increased susceptibility
to infections [33]. The standard clinical end-points are currently spirometry (forced expiratory volume in
1 s (FEV1)) and sweat chloride concentration (SCC). Both of these are influenced by non-CFTR
dependent factors, including environmental and genetic factors. These end-points have been useful for
differential diagnosis, but it is essential to develop novel models for establishment of drug efficacy in
individual patients. To this end, Beekman and co-workers used the intestinal organoid model, which is
derived from easily accessible rectal biopsies and can thus be obtained from every individual. Moreover,
organoids can be cultured for at least several months, recapitulating essential tissue features in a
self-organising system. An in vitro forskolin-induced organoid swelling (FIS) assay, mediated by
cAMP-dependent chloride pumping into the lumen, allowed for prospective drug screening with high
predictive value, being fully CFTR-dependent [34, 35]. This FIS assay was used for: 1) in vitro typing of
CFTR function in a newborn cohort; and 2) in vitro assessment of therapeutic response using multiple
modulators in different CFTR genotypes [36]. Their work demonstrated that both the in vivo
measurement of SCC and the in vitro FIS assay are able to distinguish CF phenotypes in the same way,
but only FIS allows the identification of the most severe cases [36]. In addition, they observed exciting
correlations between changes in FEV1 or SCC in vivo and changes in organoid swelling in vitro [36].
However, the two in vivo parameters did not correlate. They propose innovative CF care by generating
organoids as living biobanks that allow for personalised scientific studies with better clinical care.
Other lung diseases, such as COPD or ILDs can unfortunately not be diagnosed with such an
organoid-based system, due to the current lack of a functional readout. However, work presented by
Melanie Königshoff and colleagues showed the suitability of lung organoids for studying signalling
pathways involved in lung development, injury and repair. In both diseases epithelial damage is evident,
and diminished epithelial progenitor renewal and regeneration is thought to contribute to a disturbed lung
repair. Thus, their work aims to use alveolar organoids to gain insight into mechanisms underlying
disease, and also to understand molecular events that control and drive normal repair in order to develop
novel therapies [37–39]. Königshoff and colleagues used organoids derived from Epcam+ epithelial
progenitors of murine lung tissue, supported by the addition of fibroblasts to the culture. Fibroblasts are
https://doi.org/10.1183/23120541.00194-2018 3
BASIC AND TRANSLATIONAL SCIENCE | M.Z. NIKOLIĆ ET AL.
essential for organoid formation, although their exact role is still unclear [30, 40]. As explained above,
WNT/β-catenin signalling is involved in many aspects of lung development [41] and is also implicated in
abnormal repair responses [42–45]. To study β-catenin activity, they used a TCF/Lef-driven green
fluorescent protein (GFP) reporter and sorted GFP high and low cells and assessed the role of WNT/
β-catenin signalling in organoid formation. The colony forming efficiency of organoid formation was
analysed by assessing total nuclei per sphere and the percentage of proliferative, Ki67+ cells per sphere, as
well as expression of several differentiation markers. Interestingly, WNT/β-catenin signalling was involved
in both alveolar and airway organoid initiation, but WNT was not necessary for their proliferative
expansion. This may have important implications for COPD and specifically emphysema, as the activation
of WNT/β-catenin signalling may thus be able to initiate or improve disturbed repair responses in the lung
tissue of COPD patients. In addition, their recently published work suggests that regulation of retinoic acid
signalling is essential for epithelial progenitor growth and differentiation during lung repair processes [46].
Besides the development of new disease models, the development of novel molecular biology tools is
rapidly emerging. During this session, Patrick Harrison discussed the relatively new technology to modify
genomes using the clustered regularly interspaced short palindromic repeats (CRISPR) and
CRISPR-associated protein 9 (Cas9) system. This complex of bacterial origin consists of the Cas9 protein,
an exonuclease producing double strand DNA breaks, and a single guide RNA directing the Cas9 protein
to a specific location in the genome [47]. Thus, in theory gene modifications can be induced by simply
designing a single guide RNA for the gene of interest, and by adding a modified gene construct that will
be incorporated into the DNA at the location of interest after the double strand break by homologous
recombination. Depending on the envisaged effect, entire genes can be deleted, super-exon donors can be
inserted to activate gene expression or single base pairs can be edited to correct mutations [48]. This very
promising technology is currently mainly being investigated for the correction of monogenetic diseases,
such as α1-antitrypsin deficiency (AATD). In one recent study, the authors have attempted to correct the
AATD-causing amino acid substitution of a glutamine residue to a lysine residue in a mouse model using
an adeno-associated vector system. Of note, even if the efficacy of gene editing in the cells was rather low
(∼5%), it resulted in a functional effect and increased levels of α1-antitrypsin in blood [49]. Although the
first studies using CRISPR-Cas9 for genome modification seem encouraging, one has to keep in mind that
the safety of this technology for use to treat human disease is not yet clarified and recent reports about
CRISPR-Cas9 off-target effects (extensively reviewed in [50] further indicate the need for caution in
pushing this new technology to clinical studies.
Another intriguing application for the CRISPR-Cas9 system that was presented by Marianne Rots and
co-workers is epigenetic editing. As compared with genome editing, epigenetic editing does not aim to
introduce permanent alterations of the genome, but rather to correct aberrant epigenetic marks, in order
to influence the expression or function of a specific gene. Epigenetic marks are defined as transient but
mitotically stable changes to the DNA molecule, but not its sequence [51]. Mainly, these include DNA
methylation, histone modifications (post-translational modifications such as acetylation of methylation)
and non-coding RNAs [52]. Epigenetic marks have been described to be influenced by the environment (e.g.
smoking) [53] and their alterations have been associated with many diseases to date, including COPD [52].
This has led to the development of a new therapeutic approach to correct these aberrant marks in order to
restore or silence target gene expression, so-called epigenetic editing. In principle, an epigenetic editor
consists of an epigenetic enzyme (such as a DNA-methyltransferase) and a DNA-targeting system to bring
this editor to a specific location in the genome [54]. Thus, it is not surprising that the discovery of
CRISPR-Cas9 has also revolutionised the field of epigenetic editing, due to the ease of targeting specific
genomic regions. For this purpose, a deactivated Cas9 protein is used as double strand breaks are not
needed for epigenetic editing; indicating a possible advantage in terms of safety and prevention of
off-target effects. In one proof of principle study that identified methylation marks in the transcription
factor SAM pointed domain containing ETS transcription factor, a major regulator of mucus secretion, in
airway epithelial cells of patients with COPD [55], correction of those marks in human lung cell lines by
epigenetic editing was able to reduce the mucus production [56]. However, as discussed above there is a
need for further studies assessing the safety and in vivo efficacy of CRISPR-Cas9 based systems, and also
to optimise delivery to primary cells [52].
Most of the research discussed above has been performed in in vitro models of single cell types or
multicellular organoids. Thus, the last talk of this session, given by Martin Stampfli, focused on the
optimisation of animal models for respiratory research. The presentation reflected the results of the ERS
task force TF-2014-05 chaired by Martin Kolb and Philippe Bonniaud. The objectives of this task force
were to provide a better understanding of the complexity of animal models, to improve scientific quality
and efficacy, to avoid unethical animal research, to reduce research costs in experimental pulmonology,
and to educate young scientists about proper design, with the right approach for the right question as well
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as execution, and interpretation of findings from animal models [57]. The final aim was to move towards
the three Rs in animal experimental models: replace, reduce and refine. The results have recently been
published as an ERS statement “Optimising experimental research in respiratory diseases” [57]. The
purpose of the document is to provide guidelines to improve animal models in the respiratory medicine
field. Asthma, pneumonia, COPD and idiopathic pulmonary fibrosis (IPF) are chronic diseases for which
animal models are being used to gain insight into their pathogenesis and novel treatment options.
However, the use of animal models is not always justified and the approach is often not appropriate. Many
models have studied the effect of treatments as prevention, in diseases where that prophylactic treatment is
not feasible in clinical practice, and a therapeutic intervention is what should be sought. An example of
this is the bleomycin model for IPF that had been used since 1980 mainly for preventive treatment
approaches, but was redirected for therapeutic intervention after 2007, which lead to successful
applications in clinical practice [58–60]. It is of utmost importance to understand the similarities but also
the differences between humans and animal models, as mechanistic pathways observed in vitro might not
be replicable in vivo. Thus, the use of multiple models is recommended to facilitate reliable conclusions as
there is no model that reflects every condition in the clinic and one has to take the weaknesses and errors
of the individual model into account.
Group 3.3 mechanisms of lung injury and repair
New insights into the signalling pathways that underlie IPF pathophysiology
Besides the use and development of novel models for respiratory disease, important findings relating to
newly discovered novel therapeutic agents were discussed in an oral presentation session of scientific
abstracts in Paris. As discussed above, IPF pathogenesis is a process of excessive lung tissue repair in
response to injury that is considered a failure of normal tissue regeneration [61]. IPF is considered the
most fatal and common disease among the ILDs [62], with a mean survival rate of 3.8 years [63]. Novel
advances in understanding IPF pathophysiology, such as new insights into signalling pathways and
mechanisms are the prerequisite for the development of novel therapies. Thus, the most important
findings from presented abstracts in Paris are summarised in the following sections and grouped based on
whether they relate to collagen deposition, metabolic dysfunction, extracellular vesicles or cellular
senescence.
Collagen deposition
Fibroblast proliferation, migration and differentiation are described as central players that promote
collagen deposition in IPF lungs [63]. The abstracts presented in Paris explored collagen deposition in IPF
lungs through the following signalling pathways: 1) paired related homeobox 1 (PRRX1) transcription
factor [64], 2) FK506-binding protein 10 (FKBP10) [65], and 3) activator protein 1 (AP-1) transcription
factor Fra-2 [66].
In IPF, lung fibroblasts are known to express increased levels of activated transforming growth factor
(TGF)-β that enhances matrix metalloproteinase production and promotes collagen deposition [67]. At the
congress, fibroblast activation via transcription factor expression and collagen deposition in fibrotic lungs
was discussed, which contributes to enhanced lung matrix stiffness. One of the abstracts showed PRRX1
transcription factor as a modulator of fibroblast proliferation, migration and differentiation [64]. Another
abstract identified an increase of the transcription factor AP-1/Fra-2 in macrophages by RNA sequencing
of lungs of a mouse model for bleomycin-induced lung fibrosis model [66]. Fra-2 expression was also
associated with increased expression of collagen VI in the lungs of IPF patients [66]. Another abstract in
the session showed that knockdown of FKBP10 attenuated the expression of collagens I and IV, thereby
reducing fibroblast migration [65, 68, 69]. In line with this, FKBP10 is upregulated in IPF lungs [69].
Taken together, these three ERS abstracts showed new possible signalling pathways to target lung fibroblast
phenotype and function, as well as matrix collagen deposition. However, more comprehensive studies
describing the different types of collagen proteins, such as collagen IV, and their functional implication in
the extracellular matrix deposition and their applicability to patients are warranted.
Metabolic dysfunction
Another important pathway driving IPF pathogenesis is metabolic cell dysfunction, which mediates
fibroblast activity and death mechanisms [70]. Besides the epithelial–mesenchymal transition being
suggested as a player in IPF pathogenesis, catalytic activity of fibroblasts may also contribute to lung
fibrosis [71]. In particular, receptor tyrosine kinases and mitogen-activated protein kinases are suggested to
play a role in fibrosis development. At the 2018 ERS congress the following signalling pathways involved
in the metabolic changes in IPF were discussed: 1) growth hormone-releasing hormone (GHRH) [72], 2)
MAP kinase phosphatase 5 (MKP5) [73], and 3) glutathione peroxidase 4 (GPX4) [74].
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Mitochondrial dysfunction has been demonstrated to be increased in the plasma and bronchoalveolar
lavage of IPF patients [75], which might regulate lung mesenchymal cell injury [76]. One study presented
in Paris showed that GHRH is increased in the bleomycin-induced lung fibrosis model, and its
antagonism decreases fibrosis by reduced expression of transcription factor 3 (STAT3) and nuclear factor
(NF)-κB [72]. Moreover, another abstract from this session revealed decreased lung fibrosis by attenuation
of TGF-β signalling in MAP kinase phosphatase 5 (MKP5) knockout mice [73]. Accordingly, the abstract
presented by TSUBOUCHI et al. [74] from Japan showed TGF-β expression in IPF lungs induces lipid
peroxidation and myofibroblast differentiation. In summary, these three abstracts showed the involvement
of fibroblast metabolic dysfunction in IPF and suggest future research on this topic to develop novel
therapies. Metabolic changes in IPF may suggest an interesting mechanism of cell damage, which can
contribute to the matrix stiffness occurring in pulmonary fibrosis and can thus serve as a potential
treatable trait.
Extracellular vesicles
In this new era of cellular communication, extracellular vesicles have gained important attention in the
context of several lung diseases, including IPF pathophysiology [77]. Extracellular vesicles (EVs) are
cell-free membrane structures that facilitate intracellular communication by allowing cells to exchange
proteins, genetic material and lipids via vesicle trafficking. They can be roughly divided into three types:
exosomes, microvesicles and apoptotic bodies [77], based on their size and cellular origin. The most
extensively studied exosomes are ∼50–150 nm in size, are derived from the endosome and have therefore
been characterised by enrichment of tetraspanin membrane proteins, such as CD9, CD63, and CD81. EVs
also contain DNA, RNA and a variety of non-coding RNAs, which can be functionally transferred to a
recipient cell [78]. At the ERS congress, recent findings on EV contribution to pulmonary fibrosis from
human studies and mouse models were presented in abstracts [79]. EVs were reported to be increased in
human lung pulmonary fibrosis, thereby inducing changes in fibroblasts function in IPF [79, 80]. In this
study, exosomes were increased in the bronchoalveolar lavage of mice with bleomycin-induced fibrosis, as
well as in IPF patients. In addition, the proliferation of human lung fibrotic fibroblasts was increased upon
co-cultivation with exosomes. The observation that antibody-mediated neutralisation of WNT-5A,
accompanied by EV destruction, decreased the fibroblast proliferation in this co-cultivation supported a
role of the WNT-5A signalling pathway herein [79, 80]. Another abstract from this session showed that
collagen IV is increased in EVs in a mouse model of pulmonary fibrosis [66]. EVs are of strong interest in
tissue repair and regeneration and exosomes have already been shown to be a targetable pathway in IPF as
they are associated with matrix deposition, and disease severity [79–81].
Cell senescence
Most patients diagnosed with IPF are usually older than 50 years and cell senescence has been
demonstrated to contribute to IPF disease development [82]. Cell senescence markers, such as
senescence-associated β-galactosidase, P21, cyclin dependent kinase inhibitor 2A (P16-INK4a) and DNA
damage response have been demonstrated to be increased in injured epithelial cells in IPF [83]. Similarly,
one of the abstracts in this session discussed p16 as a regulator of ageing-related diseases [84]. In this
study, P16-INK4a knock-out mice were shown to protect epithelial alveolar type 2 cell injuries, collagen
deposition and myofibroblast differentiation in fibrosis [84]. Thus, this pathway might be a promising
target for IPF and other ageing-related diseases which affect the lung, such as COPD. Thus, cell senescence
in IPF represents a good example of a disease target for the development of therapeutics.
Future perspectives in IPF signalling pathways
Newly identified mechanisms and the underlying signalling pathways associated with the pathophysiology
of IPF are emerging from bench-to-bedside studies and vice versa. This new knowledge is being used to
improve disease characterisation and patient phenotyping, thereby ultimately leading to personalised
treatments. In addition, a comprehensive understanding of molecular, genetic and functional players
involved in the pathophysiology of IPF will help to find new therapeutic targets, thereby improving
translational medicine and patients’ treatment.
Summary
In summary, basic science is becoming increasingly visible at the annual ERS International Congress.
Importantly this brings recent developments in basic science to a largely clinical audience and thereby
provides a platform to discuss the translational value of recent studies in order for scientists and clinicians
to jointly develop novel therapeutic approaches.
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